FRINK Linked Data Fragments server

Matches in Wikidata for { <http://www.wikidata.org/entity/Q52567691> ?p ?o ?g. }

• Q52567691 description "2018 nî lūn-bûn" @default.
• Q52567691 description "2018年の論文" @default.
• Q52567691 description "2018年学术文章" @default.
• Q52567691 description "2018年学术文章" @default.
• Q52567691 description "2018年学术文章" @default.
• Q52567691 description "2018年学术文章" @default.
• Q52567691 description "2018年学术文章" @default.
• Q52567691 description "2018年学术文章" @default.
• Q52567691 description "2018年學術文章" @default.
• Q52567691 description "2018年學術文章" @default.
• Q52567691 description "2018年學術文章" @default.
• Q52567691 description "2018年學術文章" @default.
• Q52567691 description "2018年學術文章" @default.
• Q52567691 description "2018년 논문" @default.
• Q52567691 description "article científic" @default.
• Q52567691 description "article scientific" @default.
• Q52567691 description "article scientifique" @default.
• Q52567691 description "articol științific" @default.
• Q52567691 description "articolo scientifico" @default.
• Q52567691 description "artigo científico" @default.
• Q52567691 description "artigo científico" @default.
• Q52567691 description "artigo científico" @default.
• Q52567691 description "artikel ilmiah" @default.
• Q52567691 description "artikull shkencor" @default.
• Q52567691 description "artikulong pang-agham" @default.
• Q52567691 description "artykuł naukowy" @default.
• Q52567691 description "artículo científico publicado en 2018" @default.
• Q52567691 description "artículu científicu" @default.
• Q52567691 description "bilimsel makale" @default.
• Q52567691 description "bài báo khoa học" @default.
• Q52567691 description "naučni članak" @default.
• Q52567691 description "scienca artikolo" @default.
• Q52567691 description "scientific article published on 24 April 2018" @default.
• Q52567691 description "scientific article published on 24 April 2018" @default.
• Q52567691 description "scientific article published on 24 April 2018" @default.
• Q52567691 description "teaduslik artikkel" @default.
• Q52567691 description "tieteellinen artikkeli" @default.
• Q52567691 description "tudományos cikk" @default.
• Q52567691 description "vedecký článok" @default.
• Q52567691 description "vetenskaplig artikel" @default.
• Q52567691 description "videnskabelig artikel" @default.
• Q52567691 description "vitenskapelig artikkel" @default.
• Q52567691 description "vitskapeleg artikkel" @default.
• Q52567691 description "vědecký článek" @default.
• Q52567691 description "wetenschappelijk artikel" @default.
• Q52567691 description "wissenschaftlicher Artikel" @default.
• Q52567691 description "επιστημονικό άρθρο" @default.
• Q52567691 description "мақолаи илмӣ" @default.
• Q52567691 description "наукова стаття, опублікована у квітні 2018" @default.
• Q52567691 description "научна статия" @default.
• Q52567691 description "научная статья" @default.
• Q52567691 description "научни чланак" @default.
• Q52567691 description "научни чланак" @default.
• Q52567691 description "מאמר מדעי" @default.
• Q52567691 description "مقالة علمية نشرت في 24 أبريل 2018" @default.
• Q52567691 description "২৪ এপ্রিল ২০১৮-এ প্রকাশিত বৈজ্ঞানিক নিবন্ধ" @default.
• Q52567691 description "บทความทางวิทยาศาสตร์" @default.
• Q52567691 description "სამეცნიერო სტატია" @default.
• Q52567691 name "Efficacy and tolerability of initiating, or switching to, infliximab biosimilar CT-P13 in inflammatory bowel disease (IBD): a large single-centre experience." @default.
• Q52567691 name "Efficacy and tolerability of initiating, or switching to, infliximab biosimilar CT-P13 in inflammatory bowel disease (IBD): a large single-centre experience." @default.
• Q52567691 name "Efficacy and tolerability of initiating, or switching to, infliximab biosimilar CT-P13 in inflammatory bowel disease (IBD): a large single-centre experience." @default.
• Q52567691 type Item @default.
• Q52567691 label "Efficacy and tolerability of initiating, or switching to, infliximab biosimilar CT-P13 in inflammatory bowel disease (IBD): a large single-centre experience." @default.
• Q52567691 label "Efficacy and tolerability of initiating, or switching to, infliximab biosimilar CT-P13 in inflammatory bowel disease (IBD): a large single-centre experience." @default.
• Q52567691 label "Efficacy and tolerability of initiating, or switching to, infliximab biosimilar CT-P13 in inflammatory bowel disease (IBD): a large single-centre experience." @default.
• Q52567691 prefLabel "Efficacy and tolerability of initiating, or switching to, infliximab biosimilar CT-P13 in inflammatory bowel disease (IBD): a large single-centre experience." @default.
• Q52567691 prefLabel "Efficacy and tolerability of initiating, or switching to, infliximab biosimilar CT-P13 in inflammatory bowel disease (IBD): a large single-centre experience." @default.
• Q52567691 prefLabel "Efficacy and tolerability of initiating, or switching to, infliximab biosimilar CT-P13 in inflammatory bowel disease (IBD): a large single-centre experience." @default.
• Q52567691 P1154 Q52567691-BCE0019A-7E4C-4B18-A399-7C00B18D1A40 @default.
• Q52567691 P1433 Q52567691-1250F711-9980-48AE-8520-FCC4713F702B @default.
• Q52567691 P1476 Q52567691-A9FF5065-205B-458C-B696-FCC9BDE936CC @default.
• Q52567691 P2093 Q52567691-00B8BABE-5A67-40DA-B27D-E590A04FE2E7 @default.
• Q52567691 P2093 Q52567691-1C4D4D03-6D08-4BC3-91A4-60104B3CC91E @default.
• Q52567691 P2093 Q52567691-209DB751-222B-4F1D-B3B4-DD24FFD63A08 @default.
• Q52567691 P2093 Q52567691-6701ED94-38D3-431C-A106-99916D85A7B0 @default.
• Q52567691 P2093 Q52567691-73153A08-6756-4342-AF18-712B44D382C8 @default.
• Q52567691 P2093 Q52567691-8E8FEC0F-C44B-479E-8286-08F97CA1E207 @default.
• Q52567691 P2093 Q52567691-AB6A0D74-7BAB-41F6-8523-25656CB7FF34 @default.
• Q52567691 P2093 Q52567691-B8785029-19A0-416C-B1F4-AE3157B334DA @default.
• Q52567691 P2093 Q52567691-F65BFE26-1D13-4B5E-9188-B7BA80180AEE @default.
• Q52567691 P304 Q52567691-58732856-D615-4336-8667-A3E6CB994312 @default.
• Q52567691 P31 Q52567691-E368A005-2A44-44A6-9931-83B100476C51 @default.
• Q52567691 P356 Q52567691-90903ECB-AEA8-454B-A74A-46CF974576B3 @default.
• Q52567691 P50 Q52567691-075214A4-1249-4D7D-BA5C-F6F52CACED86 @default.
• Q52567691 P50 Q52567691-B970FDC5-18EC-4B0A-B74F-D98BB944E868 @default.
• Q52567691 P577 Q52567691-E3BFCE17-3E4D-4916-84C9-C4213A90EF1D @default.
• Q52567691 P6366 Q52567691-14AE08FD-3BB1-46E3-8C49-787EF323D0B5 @default.
• Q52567691 P698 Q52567691-2C79D2ED-91C8-4E01-A1E4-AABFA255AF5B @default.
• Q52567691 P921 Q52567691-73FF8AE9-F9E1-4A71-A59C-4AAB9381EE2D @default.
• Q52567691 P953 Q52567691-798F700C-B532-4AC4-99C9-F416937EEFCA @default.
• Q52567691 P356 00365521.2018.1464203 @default.
• Q52567691 P6366 2799534621 @default.
• Q52567691 P698 29687730 @default.
• Q52567691 P1154 "2-s2.0-85046038678" @default.
• Q52567691 P1433 Q7429960 @default.
• Q52567691 P1476 "Efficacy and tolerability of initiating, or switching to, infliximab biosimilar CT-P13 in inflammatory bowel disease (IBD): a large single-centre experience." @default.
• Q52567691 P2093 "Anthony O'Connor" @default.
• Q52567691 P2093 "Christian P Selinger" @default.
• Q52567691 P2093 "Katherine Leigh" @default.
• Q52567691 P2093 "Lynsey Bourner" @default.

• next